Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

48.87
+0.54001.12%
Volume:1.30M
Turnover:63.10M
Market Cap:8.20B
PE:125.88
High:49.03
Open:48.05
Low:47.64
Close:48.33
52wk High:55.67
52wk Low:25.17
Shares:167.76M
Float Shares:155.00M
Volume Ratio:1.11
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:4.53
PE(LYR):34.17

Loading ...

Alkermes director Christopher I. Wright disposes of USD 90,200 in common shares

Reuters
·
Jun 13

Should Alkermes’ (ALKS) Sleep-Medicine Pivot After Lumryz and Alixorexton Data Require Investor Action?

Simply Wall St.
·
Jun 12

Alkermes’ alixorexton granted orphan designation for idiopathic hypersomnia

TIPRANKS
·
Jun 12

Mizuho Securities Sticks to Their Buy Rating for Alkermes (ALKS)

TIPRANKS
·
Jun 10

Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says

MT Newswires Live
·
Jun 09

RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating

MT Newswires Live
·
Jun 09

Alkermes Plc : RBC Raises Target Price to $56 From $45

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
Jun 08

A Look At Alkermes (ALKS) Valuation After 28.2% Revenue Growth And Strengthening Analyst Optimism

Simply Wall St.
·
Jun 05

Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $87,569.7

Reuters
·
Jun 05

Alkermes to present new data on Alixorexton, LUMRYZ

TIPRANKS
·
Jun 04

Alkermes presents new phase 2 Vibrance-2 data for alixorexton in narcolepsy type 2 at SLEEP 2026

Reuters
·
Jun 04

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)

TIPRANKS
·
Jun 04

Alkermes to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 04

Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story?

Simply Wall St.
·
Jun 03

Alkermes Chief Medical Officer Craig Hopkinson sells 9,000 shares for $375,044‬

Reuters
·
Jun 02

Alkermes VP Finance Samuel Joseph Parisi disposes of 16,217 shares for $686,807.86

Reuters
·
May 30

Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target

TIPRANKS
·
May 29

Alkermes presents Phase 2 Vibrance-1 data on alixorexton in narcolepsy type 1 at ASCP meeting

Reuters
·
May 26

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

THOMSON REUTERS
·
May 26